Research Article Preoperative Peripheral Blood Count in Breast Carcinoma: Predictor of Prognosis or a Routine Test Amrit Pal Singh Rana, 1 Manjit Kaur, 2 B. Zonunsanga, 1 Arun Puri, 2 and Amarjit Singh Kuka 1 1 Department of Surgery, GGS Medical College, Faridkot 151203, India 2 Department of Pathology, GGS Medical College, Faridkot 151203, India Correspondence should be addressed to Amrit Pal Singh Rana; dramritpalsingh@gmail.com Received 25 July 2015; Revised 8 November 2015; Accepted 11 November 2015 Academic Editor: Vladimir F. Semiglazov Copyright © 2015 Amrit Pal Singh Rana et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Peripheral blood count is the frst investigation to be done in every patient before surgery. As strong relationship exists between cancer and immune response of the body, clinical stage at presentation and altered hematological parameters can infuence the progression of cancer and vice versa. Settings and Design. It is a case control study of total 50 cases (35 cases of carcinoma breast and 15 cases of benign breast disease). Methods. A case control study was carried out; 35 cases of breast cancer patients were taken prior to surgery and chemotherapy with 15 cases of benign breast disease as control. Clinical staging according to the tumor, node, and metastasis classifcation (TNMc) was done and was correlated with complete blood count (CBC). Results. All the cancer patients were females with overall mean age of 47.96 ± 13.84 years. Amongst all altered blood parameters, correlation of absolute lymphocytic count ( value 0.001) with TNMc staging was found signifcant. Particularly, decrease in absolute leucocytic count was observed with increase in stage of breast carcinoma. Conclusions. Te stage-specifc mean values of absolute lymphocytic counts of preoperative breast cancer patients can be used as an economical tool to know the evolution of disease. 1. Introduction Complete blood count especially lymphocytic count refects the response of cellular immunity in a cancer patient. Any alteration in hematological parameters infuences the disease progression. Depending upon the clinical presen- tation (TNMc staging), response of various hematological parameters has been correlated and studied. Hemoglobin (Hb) and packed cell volume (PCV) are indirectly associated with increased risk of cardiac failure in cancer patients [1]. Total leucocytic count (TLC), if elevated, predicts poorer prognosis [2]. Te prognostic signifcance of neutrophils, lymphocytes, plasma cells, mean platelet volume (MPV), platelet/lymphocyte ratio, and neutrophil/lymphocyte ratio studied in gastric cancer patients showed infuence on overall survival [3]. So it is also important to study complete blood count in breast carcinoma and its correlation with TNMc staging. 2. Methods Tis was a case control study carried among the breast cancer patients (35 cases) who have undergone breast surgeries at a tertiary health care centre. Patients who had taken chemo- therapy were excluded. Breast cancer patients were staged prior to surgery. Te patients were staged clinically according to the tumor, node, and metastasis (TNM) classifcation. Stage I tumor is <2 cm in greatest dimension, with no nodal involvement and no metastasis. Stage II ranges from none- vident tumor to tumor >5 cm in greatest dimension with either no nodal involvement or metastases in movable ipsilat- eral axillary lymph node(s) but no distant metastases. Stage III tumor size ranges from either not evident to tumor of any size with direct extension to (a) chest wall or (b) skin, with no evidence of regional lymph node metastases or meta- stases in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement or in clinically Hindawi Publishing Corporation International Journal of Breast Cancer Volume 2015, Article ID 964392, 5 pages http://dx.doi.org/10.1155/2015/964392